| Literature DB >> 31491820 |
Ziren Kong1, Chendan Jiang1, Ruizhe Zhu2, Shi Feng2, Yaning Wang1, Jiatong Li3, Wenlin Chen1, Penghao Liu1, Dachun Zhao4, Wenbin Ma1, Yu Wang1, Xin Cheng5.
Abstract
The differential diagnosis of primary central nervous system lymphoma from glioblastoma multiforme (GBM) is essential due to the difference in treatment strategies. This study retrospectively reviewed 77 patients (24 with lymphoma and 53 with GBM) to identify the stable and distinguishable characteristics of lymphoma and GBM in 18F-fluorodeocxyglucose (FDG) positron emission tomography (PET) images using a radiomics approach. Three groups of maps, namely, a standardized uptake value (SUV) map, an SUV map calibrated with the normal contralateral cortex (ncc) activity (SUV/ncc map), and an SUV map calibrated with the normal brain mean (nbm) activity (SUV/nbm map), were generated, and a total of 107 radiomics features were extracted from each SUV map. The margins of the ROI were adjusted to assess the stability of the features, and the area under the curve (AUC) of the receiver operating characteristic curve of each feature was compared with the SUVmax to evaluate the distinguishability of the features. Nighty-five radiomics features from the SUV map were significantly different between lymphoma and GBM, 46 features were numeric stable after marginal adjustment, and 31 features displayed better performance than SUVmax. Features extracted from the SUV map demonstrated higher AUCs than features from the further calibrated maps. Tumors with solid metabolic patterns were also separately evaluated and revealed similar results. Thirteen radiomics features that were stable and distinguishable than SUVmax in every circumstance were selected to distinguish lymphoma from glioblastoma, and they suggested that lymphoma has a higher SUV in most interval segments and is more mathematically heterogeneous than GBM. This study suggested that 18F-FDG-PET-based radiomics is a reliable noninvasive method to distinguish lymphoma and GBM.Entities:
Keywords: (18)F-FDG; Glioblastoma; Lymphoma; Positron emission tomography; Radiomics
Mesh:
Substances:
Year: 2019 PMID: 31491820 PMCID: PMC6702330 DOI: 10.1016/j.nicl.2019.101912
Source DB: PubMed Journal: Neuroimage Clin ISSN: 2213-1582 Impact factor: 4.881
Fig. 1Example of the three-dimensional tumor segmentation (red area) and marginal expansion (green area). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Characteristics of the lymphoma and glioblastoma patients.
| Characteristics | Lymphoma | Glioblastoma | |
|---|---|---|---|
| Sex | 0.045 | ||
| Male | 11 (45.8%) | 37 (69.8%) | |
| Female | 13 (54.2%) | 16 (30.2%) | |
| Age (mean ± SD) | 58.83 ± 12.67 | 53.42 ± 14.83 | 0.125 |
| SUVmax (mean ± SD) | 23.76 ± 8.26 | 13.50 ± 4.37 | < 0.001 |
| T/N ratio (mean ± SD) | 5.77 ± 1.90 | 4.13 ± 1.37 | 0.001 |
| MTV (mean ± SD) | 23.06 ± 24.07 | 44.50 ± 39.40 | 0.004 |
| TLG (mean ± SD) | 565.24 ± 539.03 | 385.89 ± 404.12 | 0.109 |
| Lesion number | 0.007 | ||
| Single | 16 (66.7%) | 52 (98.1%) | |
| Multiple | 8 (33.3%) | 1 (1.9%) | |
| Metabolic pattern | < 0.001 | ||
| Solid | 21 (87.5%) | 21 (39.6%) | |
| Cystic | 3 (12.5%) | 32 (60.4%) |
Abbreviations: SUV, standardized uptake value; T/N, tumor to normal contralateral cortex activity; MTV, metabolic tumor volume; TLG, total lesion glycolysis.
Fig. 2Heat maps of all radiomics features in the whole population (A), the 31 distinguishing features in the whole population (B), and the 25 distinguishing features in the solid metabolic tumors (C). Heat maps were clustered by pathological information, with the blue column on the left indicating lymphoma patients and the yellow column indicating glioblastoma patients. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 3Name and performance of the features that had better differentiation performance than ‘First order_Maximum’ in any of the 12 situations. The performances of ‘First order_Maximum’ are labeled in green at the bottom of the figure, and features that outperformed ‘First order_Maximum’ are labeled in red, with a stronger color indicating higher AUC values. Features that performed worse than ‘First order_Maximum’ are labeled blue. Abbreviations: T, tumor; ncc, calibrated by the normal contralateral cortex activity; nbm, calibrated by the normal brain mean activity; ma, marginal adjustment; sm, solid metabolic. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
The discrimination performance of the selected radiomics features in comparison with ‘First order_Maximum’.
| Selected features | AUC | ACC | SEN | SPE | PRE | REC | ICC |
|---|---|---|---|---|---|---|---|
| First order_90 percentile | 0.984 | 0.948 | 0.943 | 0.958 | 0.980 | 0.943 | 0.793 |
| First order_Mean | 0.980 | 0.948 | 0.962 | 0.917 | 0.962 | 0.962 | 0.803 |
| First order_Median | 0.977 | 0.948 | 0.962 | 0.917 | 0.962 | 0.962 | 0.792 |
| First order_Root mean squared | 0.984 | 0.961 | 0.981 | 0.917 | 0.963 | 0.981 | 0.807 |
| GLCM_Contrast | 0.986 | 0.948 | 0.962 | 0.917 | 0.962 | 0.962 | 0.593 |
| GLCM_Difference average | 0.990 | 0.948 | 0.943 | 0.958 | 0.980 | 0.943 | 0.765 |
| GLCM_Difference entropy | 0.976 | 0.935 | 0.962 | 0.875 | 0.944 | 0.962 | 0.789 |
| GLCM_Difference variance | 0.971 | 0.909 | 0.906 | 0.917 | 0.960 | 0.906 | 0.580 |
| GLCM_Inverse difference | 0.991 | 0.935 | 0.906 | 1.000 | 1.000 | 0.906 | 0.811 |
| GLCM_Inverse difference moment | 0.991 | 0.935 | 0.906 | 1.000 | 1.000 | 0.906 | 0.819 |
| GLRLM_Run length non-uniformity normalized | 0.998 | 0.974 | 0.962 | 1.000 | 1.000 | 0.962 | 0.835 |
| GLRLM_Run percentage | 0.991 | 0.974 | 0.981 | 0.958 | 0.981 | 0.981 | 0.793 |
| GLDM_Large dependence emphasis | 0.987 | 0.974 | 0.981 | 0.958 | 0.981 | 0.981 | 0.724 |
| First order_Maximum (comparison) | 0.943 | 0.883 | 0.887 | 0.875 | 0.940 | 0.887 | 0.716 |
Abbreviations: GLCM, grey-level co-occurrence matrix; GLRLM, grey level run length matrix; GLDM, grey level dependence matrix; AUC, area under curve; ACC, accuracy; SEN, sensitivity; SPE, specificity; PRE, precision rate; REC, recall rate; ICC, intraclass correlation coefficient.
The area under curve values based on cross validation in six circumstances with whole population.
| Selected features | T | T.ncc | T.nbm | T.ma | T.ma.ncc | T.ma.nbm |
|---|---|---|---|---|---|---|
| First order_90 percentile | 0.850 | 0.941 | 0.967 | 0.929 | 0.801 | 0.829 |
| First order_Mean | 0.833 | 0.757 | 0.878 | 0.750 | 0.900 | 0.857 |
| First order_Median | 0.969 | 0.801 | 0.944 | 0.857 | 0.800 | 0.900 |
| First order_Root mean squared | 0.938 | 0.740 | 0.955 | 0.800 | 0.821 | 0.889 |
| GLCM_Contrast | 0.893 | 0.705 | 1.000 | 0.864 | 0.847 | 0.875 |
| GLCM_Difference average | 0.917 | 0.714 | 0.969 | 0.958 | 0.717 | 1.000 |
| GLCM_Difference entropy | 0.857 | 0.795 | 0.967 | 0.857 | 0.878 | 0.964 |
| GLCM_Difference variance | 0.784 | 0.958 | 0.929 | 0.875 | 0.781 | 0.917 |
| GLCM_Inverse difference | 0.955 | 0.917 | 0.829 | 0.929 | 0.815 | 0.892 |
| GLCM_Inverse difference moment | 0.857 | 0.702 | 0.864 | 0.900 | 0.750 | 0.839 |
| GLRLM_Run length non-uniformity normalized | 0.964 | 0.833 | 1.000 | 0.969 | 0.833 | 0.962 |
| GLRLM_Run percentage | 0.955 | 1.000 | 0.857 | 0.964 | 0.800 | 0.900 |
| GLDM_Large dependence emphasis | 0.929 | 0.900 | 0.900 | 1.000 | 0.900 | 0.889 |
| First order_Maximum (comparison) | 0.750 | 0.690 | 0.815 | 0.750 | 0.739 | 0.762 |
Abbreviations: T, tumor; ncc, calibrated by the normal contralateral cortex activity; nbm, calibrated by the normal brain mean activity; ma, marginal adjustment; GLCM, grey-level co-occurrence matrix; GLRLM, grey level run length matrix; GLDM, grey level dependence matrix.
Fig. 4Radiomics maps of the selected radiomics features in a lymphoma patient (A) and a glioblastoma patient (B). First order features demonstrated a higher SUV in the region of interest and the texture features displayed a more mathematically heterogeneous of lymphomas. Although the radiomics maps presented here are different from what have been calculated in radiomics feature analysis, they provide an intuitive way for visualization.
Selected radiomics features, their discrimination performances and threshold value.
| Selected features | Threshold | Values of two specific patients | ||
|---|---|---|---|---|
| Lymphoma | Glioblastoma | Performance | ||
| First order_90 percentile | 11.72 | 14.51 | 10.81 | Accurate |
| First order_Mean | 8.380 | 12.12 | 7.508 | Accurate |
| First order_Median | 8.171 | 11.98 | 7.236 | Accurate |
| First order_Root mean squared | 9.430 | 12.24 | 7.822 | Accurate |
| GLCM_Contrast | 1.126 | 1.167 | 0.7556 | Accurate |
| GLCM_Difference average | 0.747 | 0.7672 | 0.5762 | Accurate |
| GLCM_Difference entropy | 1.500 | 1.504 | 1.313 | Accurate |
| GLCM_Difference variance | 0.484 | 0.5463 | 0.4126 | Accurate |
| GLCM_Inverse difference | 0.686 | 0.6763 | 0.7396 | Accurate |
| GLCM_Inverse difference moment | 0.670 | 0.6561 | 0.7298 | Accurate |
| GLRLM_Run length non-uniformity normalized | 0.508 | 0.5174 | 0.3889 | Accurate |
| GLRLM_Run percentage | 0.651 | 0.6555 | 0.5280 | Accurate |
| GLDM_Large dependence emphasis | 122.4 | 121.8 | 205.2 | Accurate |
Abbreviations: GLCM, grey-level co-occurrence matrix; GLRLM, grey level run length matrix; GLDM, grey level dependence matrix.